Clene Inc. Reports 70% Revenue Decline in Q2 2025, Plans for Funding Options

Clene Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $27,000, a significant decrease of 70% compared to $91,000 in the same period last year. For the first half of 2025, the company generated $108,000 in revenue, down 34% from $164,000 in the first half of 2024. The decline in revenue was attributed primarily to reduced product sales and royalty income from dietary supplements, which are sold through its subsidiary, dOrbital, Inc., and under a license agreement with 4Life Research LLC.

Operating expenses for the second quarter of 2025 were $5.9 million, a 21% decrease from $7.5 million in the prior year. The reduction in expenses was driven by lower research and development costs, which fell to $3.5 million from $4.2 million, and a decrease in general and administrative expenses, which dropped to $2.4 million from $3.3 million. The net loss for the quarter was $7.4 million, compared to a loss of $6.8 million in the same quarter of 2024. For the first half of 2025, the net loss was $8.2 million, a 54% improvement from a loss of $17.9 million in the first half of 2024.

Clene Inc. continues to focus on its clinical-stage drug candidates, particularly CNM-Au8, which is being developed for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company is currently engaged in discussions with the FDA regarding an accelerated approval pathway for CNM-Au8, with plans to submit a New Drug Application (NDA) by the end of 2025, contingent on the collection of additional data from ongoing clinical trials.

As of June 30, 2025, Clene reported total assets of $22.1 million, down from $27.3 million at the end of 2024. The company had cash and cash equivalents of $7.3 million, a decrease from $12.2 million at the end of the previous year. Clene's accumulated deficit increased to $290.3 million, reflecting ongoing operational losses. The company has indicated that it will need to secure additional financing to sustain its operations and continue its clinical development programs, as it anticipates further losses in the near future.

Looking ahead, Clene Inc. plans to explore various funding options, including equity financing and collaboration arrangements, to address its liquidity needs. The company has implemented cost-saving measures, including reducing research and development expenditures and staff positions, but acknowledges that these efforts may not fully alleviate concerns regarding its ability to continue as a going concern.